14 hrs ago | Fox News
Cephalon to Sue Teva for Patent Infringement
Pharmaceutical company Cephalon, Inc. announced Wednesday that it has filed a suit in a Delaware District Court against Teva Pharmaceuticals USA, Inc.
The South Mississippi Sun Herald
Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Cephalon, Inc. today announced that it has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc.
Guru Stocks at 52-Week Low: MFG, CEPH, EM, APEI, WTNY
Last week's top five stocks that ended close to their 52-week lows were Mizuho Financial Group Inc, Cephalon Inc, Emdeon Inc, American Public Education, and Whitney Holding Corp.
Stocks in the Spotlight Monday
Dow Jones Reprints: This copy is for your personal, non-commerical use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool on any article or visit www.djreprints.com Cephalon Shares of the biopharmaceuticals company slipped 8.6% on news of mixed results for reslizumab in ...
Customer Interaction Solutions
Q, BG, CEPH, RDY, MCCC, ELN Are Seasonally Ripe To Go Higher In The Next 5 Weeks
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Qwest Communications , Bunge Limited , Cephalon , Dr.
Cephalon Drug Shows Mixed Results
Cephalon shares are falling today on disappointing results from a drug to treat pediatric eosinophilic esophagitis, an inflammation of the esophagus.
Ception Therapeutics And Cephalon Provide Initial Results Of A Phase...
Main Category: GastroIntestinal / Gastroenterology Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 24 Nov 2009 - 1:00 PST Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc.
A Big Upgrade for Allos Therapeutics
Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks.
Cinquil results from Ception, Cephalon
Ception Therapeutics Inc. and Cephalon Inc. announced mixed results Monday for late-stage testing of Cinquil, an experimental drug the two suburban Philadelphia biotechnology companies are developing to treat pediatric eosinophilic esophagitis.
Technically Speaking, Market Analysis...
Tuesday, November 17, 2009 Money Talks Click charts to enlarge. Will the financials lead us higher or not? Here's the Financial SPDR ...there's an island gap , a recent symmetrical triangle, and a possible head-and-shoulders top .
Par Pharma gets FDA approval for generic Ultram ER
Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid.
Cephalon, Barr settle Fentora dispute
Cephalon Inc. will give Barr Pharmaceuticals Inc. a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement, according to a Securities and Exchange Commission filing Thursday.
Bulls Buy Cephalon, WebMD:Options Recap
Utility AES sees spate of call selling : The electric utility has been dead money for the last three months, and now one investor may be throwing in the towel.
Liberty Property sell W. Chester building
A flex building in West Chester traded for $12 million, or more than $90 a square foot, in what is a strong showing for that type of building.
Pivotal Data Published In The Journal Cancer Demonstrate That TREANDA ...
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Cephalon, Inc.
Journal Cancer Publishes Pivotal Study of TREANDA in Patients with in Relapsed Indolent NHL
" November 5, 2009 - " Cephalon, Inc. today announced the journal Cancer has published a pivotal study demonstrating that TREANDAA for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma whose disease had progressed during or within six months of treatment with rituximab.
Alkermes Inc. Reports Operating Results
Alkermes Inc. filed Quarterly Report for the period ended 2009-09-30. Alkermes Inc.
Cephalon specializes in bio-pharmaceuticals that target central nervous system disorders, pain treatments, and oncology .
Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder .
Vanguard Healthcare Fund Buys Q3 Portfolio: CEPH, JNJ, ONXX, CBST
If you think to invest in healthcare industry amid the government controlled reform, you may want to look at Edward Owens a TM Vanguard Healthcare Fund portfolio.
Also on Topix